NCT02628444View on ClinicalTrials.gov

Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age

PHASE2CompletedINTERVENTIONAL

Enrollment

1,050

Participants

Timeline

Start Date

May 2, 2016

Primary Completion Date

April 29, 2020

Study Completion Date

April 29, 2020

Conditions

Dengue FeverDengue Hemorrhagic Fever

Interventions

BIOLOGICAL

CYD Dengue Vaccine

0.5 mL, Subcutaneous

BIOLOGICAL

Placebo (Sodium chloride 0.9%)

0.5 mL, Subcutaneous

Trial Locations (6)

Unknown

Investigational Site 102, Barranquilla

Investigational Site 103, Medellín

Investigational Site 101, Santiago de Cali

Investigational Primary Site Muntinlupa 201_Satellite Site San Pablo 202, City of Muntinlupa

Investigational Site 203, Manila

Investigational Site 204, Manila

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02628444 - Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age | Biotech Hunter | Biotech Hunter